Palmoplantar pustulosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Palmoplantar pustulosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis https://clinicaltrials.eu/trial/a-study-testing-how-well-bimekizumab-works-and-how-safe-it-is-for-adults-with-palmoplantar-pustulosis/ Wed, 29 Apr 2026 15:08:18 +0000 https://clinicaltrials.eu/trial/a-study-testing-how-well-bimekizumab-works-and-how-safe-it-is-for-adults-with-palmoplantar-pustulosis/ This study is looking at a condition called palmoplantar pustulosis, which is a skin disease that causes painful blisters filled with fluid to appear on the palms of the hands and soles of the feet. People with this condition often experience pain and discomfort that can affect their daily activities and quality of life. The treatment being tested in this study is called bimekizumab, which is given as an injection under the skin. Some people in the study will receive bimekizumab while others will receive placebo. The purpose of the study is to evaluate the efficacy of bimekizumab compared with placebo in participants with palmoplantar pustulosis at Week 16.

During the study, participants will receive their assigned treatment through injections that are given using pre-filled syringes or pre-filled pens. The study will measure how well the treatment works by looking at changes in the skin condition, including the number and severity of pustules on the hands and feet. Doctors will use specific scoring systems to track improvements in the skin. The study will also look at how the treatment affects pain levels and quality of life by asking participants to complete questionnaires about their symptoms and how the condition impacts their daily activities.

The study has two parts: a main treatment period and an open-label extension period where all participants may receive the active treatment. Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. They will track all health problems that occur during the study, including serious health issues and any problems that might cause participants to stop taking the study treatment. Regular check-ups and assessments will be conducted to ensure participant safety and to measure how well the treatment is working over time.

]]> Study of Delgocitinib Cream for Adults with Mild to Severe Palmoplantar Pustulosis: A 16-Week Treatment Trial https://clinicaltrials.eu/trial/study-of-delgocitinib-cream-for-adults-with-mild-to-severe-palmoplantar-pustulosis-a-16-week-treatment-trial/ Wed, 29 Apr 2026 15:06:39 +0000 https://clinicaltrials.eu/trial/study-of-delgocitinib-cream-for-adults-with-mild-to-severe-palmoplantar-pustulosis-a-16-week-treatment-trial/ This study focuses on adults with palmoplantar pustulosis, a skin condition that causes persistent pustules on the palms of hands and/or soles of feet, lasting for more than 3 months. The condition may occur with or without psoriasis on other parts of the body. The study will test a new medication called delgocitinib in cream form against a cream without active ingredients (cream vehicle).

The purpose of this research is to evaluate how well delgocitinib cream works when applied twice daily for treating mild to severe palmoplantar pustulosis. The cream contains 20 milligrams of the active substance per gram. The treatment period will last 16 weeks, during which participants will apply the cream to affected areas of their palms and/or soles.

During the study, participants will be randomly assigned to receive either delgocitinib cream or the cream vehicle. The study is double-blind, which means neither the participants nor the healthcare providers will know which cream is being used. The maximum daily amount of cream that can be applied is 2.5 grams, with a total maximum amount of 280 grams throughout the entire study period.

]]> Study on the Effects of Sonelokimab for Patients with Moderate-to-Severe Palmoplantar Pustulosis https://clinicaltrials.eu/trial/study-on-the-effects-of-sonelokimab-for-patients-with-moderate-to-severe-palmoplantar-pustulosis/ Wed, 29 Apr 2026 14:59:13 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-sonelokimab-for-patients-with-moderate-to-severe-palmoplantar-pustulosis/ This clinical trial is focused on studying a skin condition called Palmoplantar Pustulosis, which is characterized by the appearance of pustules on the palms of the hands and the soles of the feet. The study will explore the effects of a treatment called Sonelokimab, which is administered as an injection under the skin. The purpose of the study is to evaluate how effective Sonelokimab is in improving the condition of the skin in patients with moderate-to-severe Palmoplantar Pustulosis.

Participants in the study will receive Sonelokimab injections over a period of 16 weeks. During this time, the study will monitor changes in the severity of the skin condition using a specific measure known as the Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI). This index helps to assess the extent and severity of the skin condition. The study aims to see if there is an improvement in the PPPASI score from the beginning of the study to the end of the 16-week period.

The study is open-label, meaning that both the participants and the researchers will know that Sonelokimab is being administered. This trial is being conducted at multiple centers, allowing for a diverse group of participants. The results of this study will help to determine the potential benefits of Sonelokimab for individuals suffering from moderate-to-severe Palmoplantar Pustulosis.

]]>